Full Text View
Tabular View
No Study Results Posted
Related Studies
A 14-Week, Multi-Center Study of [S,S]-Reboxetine in Patients With Fibromyalgia.
This study has been completed.
Study NCT00612170   Information provided by Pfizer
First Received: January 29, 2008   Last Updated: July 9, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Fibromyalgia
Additional conditions recognized in this trial
Myofascial Pain Syndromes
More general conditions related to this trial
Muscular Diseases
Musculoskeletal Diseases
Nervous System Diseases
Neuromuscular Diseases
Rheumatic Diseases
Interventions listed in this trial
[S,S]-Reboxetine
Placebo
Additional drug interventions recognized in this trial
Reboxetine
More general drug interventions related to this trial
Adrenergic Agents
Adrenergic Uptake Inhibitors
Antidepressive Agents
Central Nervous System Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Therapeutic Uses
Sponsors listed in this trial
Pfizer


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services